Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

OP experienced thicker hair and less shedding with Nutrafol Women’s Balance but had flushing due to ingredients, and is considering switching to Viviscal Pro with saw palmetto. A user shared that Viviscal increased shedding for both him and his girlfriend, and suggested stopping Nutrafol if the hair loss is due to Telogen effluvium.

A user is considering a hair transplant for density and is unsure whether to choose Reviva or Darling Buds, with Reviva being cheaper. Another user advises against Reviva due to poor experiences and suggests considering medication for hair density instead.

Amplifica is developing new molecules for hair growth, with clinical trials expected soon, while Engraft Technologies is improving FUE robotic technology to make hair transplants faster and cheaper. Users express interest in the timeline for AMP-303 and concerns about high costs and effectiveness of current treatments.

The conversation discusses using a violet ray device for hair regrowth, citing a case where zinc ion treatments showed promising results. It also mentions similar devices like the Growcombr and niostem helmet.

People are discussing the Regenera Activa stem cell treatment for hair loss, expressing interest and seeking feedback on its effectiveness. Some are considering traveling to Singapore for the procedure, which costs £2000 in the UK.

Amplifica raised $26 million to advance its injectable treatments for hair growth. The funding will support the clinical development of their novel therapies.

Revivhair serum is discussed as a potential treatment for mild hair thinning, but skepticism exists about its effectiveness without proven treatments like finasteride, dutasteride, or minoxidil. Users share experiences with various treatments, noting side effects and exploring alternatives like topical dutasteride and alfatradiol.

The conversation is about hair loss treatments, specifically using finasteride, minoxidil, and biotin, with a focus on the effectiveness of Hims products. Users discuss the results, potential side effects, and the role of biotin in the treatment.

Amplifica's AMP-303 showed a modest increase in hair growth, but results were inconsistent and potentially misleading. Hyaluronic acid and osteopontin are being explored for hair growth, with varying effects on different hair types and conditions.

Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.

The conversation is about a user's hair loss treatment progress using minoxidil, finasteride, and red light therapy. The user plans to continue using a combination of finasteride, minoxidil, and biotin, and uses a FIVORRA red light therapy hat.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

A 26-year-old male shared progress pictures of hair regrowth using topical Minoxidil 5% twice daily, Finasteride 1mg daily, Vitamin D supplements, and coconut oil. Users discussed the effectiveness and side effects of these treatments, with positive feedback on the visible improvements.

The user is using oral finasteride, minoxidil, and KX-826 for hair regrowth, noticing small improvements. They plan to add ketoconazole shampoo and consider a hair transplant with verteporfin after a year of treatment.

The user experienced significant hair regrowth using finasteride, minoxidil, Nizoral, dermapen, and PRP sessions. They also made lifestyle changes like quitting smoking and alcohol, resulting in thicker and denser hair.

The VT Reedle Shot, a skincare product using silica spicules, is discussed as a potential at-home alternative to microneedling for hair regrowth. It is suggested that different intensities may aid in hairline regrowth.

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.

Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

A 25-year-old is using vinpocetine to enhance the absorption of topical Minoxidil for hair loss. They also use a hair tonic and supplement with Glycine, Taurine, Creatine, and Citrulline.

The user shared progress on hair regrowth using oral dutasteride, oral minoxidil, and verteporfin procedures. They reported some regrowth after 6-9 months of treatment.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.